How Has Biogen Soared 61% This Year, But Still Costs Only $1?
Biogen (NASDAQ: BIIB) is the latest biotech stock to light up investment news after a bombshell announcement. One of the company’s drugs received unexpected clearance from the FDA, opening the door to monstrous profits in the near future. Shares leaped more than 60% to $407 on the news. That’s a hefty price tag that might be prohibitive for some investors, but there’s a simple strategy that you can use that makes Biogen affordable for anyone.
Biogen’s big news
A 61% year-to-date return is spectacular, but it might surprise you to see that these gains were achieved in a matter of days.
Prior to the recent jump, the stock was fairly flat for 18 months. It bounced around a good amount between $250 and $350 per share, but it never moved decisively in either direction.
On June 7, the company announced that it had received FDA clearance for accelerated approval of its drug ADUHELM. ADUHELM treats Alzheimer’s disease by reducing plaque buildup in the brain, and it could be the first genuinely effective pharmaceutical treatment to combat the debilitating illness.
That was very bullish news for investors, and it was compounded by Biogen’s eye-popping pricing for ADUHELM. The company indicated that it would charge $56,000 yearly per patient for treatment with the drug. Some politicians have already condemned the high price tag as exploitative, and there’s a good chance that Medicare will be able to negotiate to reduce the cost. Still, it’s an enormous revenue opportunity. Early forecasts range from $5 billion to $12 billion in peak annual sales.
Investors should recognize that Biogen’s success isn’t quite guaranteed. Some doctors on the FDA panel actually opposed the clearance, citing doubts about the efficacy of the drug. There’s an ongoing post-approval study currently under way, so there will be more data collected that could jeopardize its viability. There are also potential competitors in clinical trials right now. Things are still subject to change, but the surprise announcement was a major step forward that reduced investment risk for Biogen shareholders.
Anyone can afford Biogen stock
Many investors, especially younger people who are just starting to build savings, might be dismayed by Biogen’s $400 share price. That’s definitely an issue if you’re excited about the story and want to throw some money at it.
The average brokerage account balance is around $10,000 for people in their 20s, and $30,000 for people in their 30s. A single share of Biogen would make up a big chunk of most younger investors’ portfolios. You’d have to feel really bullish about the company to take on that much exposure. Even if you’re optimistic about the pharmaceutical stock, it’s risky to put so many eggs into one basket immediately following great news.
That’s exactly why fractional shares were invented and have become so popular in recent years. Fractional shares allow investors to choose the dollar amount they want to purchase. You don’t need to buy a whole share of Biogen. Instead, you can buy a portion of a share. If your broker allows $1 trades, then you could buy around 1/400th of a Biogen share. Many of the reputable and popular online stock brokerages provide fractional trading, and a good portion of them allow trades as low as $1.
This is great if you don’t have enough cash to purchase a full share of Biogen, or if you just want to allocate your portfolio in a way that requires more flexibility. With other popular stocks such as Berkshire Hathaway, Alphabet, and Amazon boasting incredibly high individual share prices, this is an important feature to consider when choosing a brokerage service that’s best for you.
10 stocks we like better than Biogen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Biogen wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 7, 2021
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Ryan Downie owns shares of Alphabet (A shares) and Amazon. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, and Berkshire Hathaway (B shares). The Motley Fool recommends Biogen and recommends the following options: long January 2022 $1,920 calls on Amazon, long January 2023 $200 calls on Berkshire Hathaway (B shares), short January 2022 $1,940 calls on Amazon, short January 2023 $200 puts on Berkshire Hathaway (B shares), and short January 2023 $265 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.